Search

Search results

410 results found

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.

Kirby, Joslyn S, Martin M Okun, Afsaneh Alavi, Falk G Bechara, Christos C Zouboulis, Kurt Brown, Leandro L Santos, et al. 2024. “Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib (INCB054707) in Patients With Hidradenitis Suppurativa in a Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study.”. Journal of the American Academy of Dermatology 90 (3): 521-29.

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.

Kimball, Alexa B, Gregor B E Jemec, Afsaneh Alavi, Ziad Reguiai, Alice B Gottlieb, Falk G Bechara, Carle Paul, et al. 2023. “Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa (SUNSHINE and SUNRISE): Week 16 and Week 52 Results of Two Identical, Multicentre, Randomised, Placebo-Controlled, Double-Blind Phase 3 Trials.”. Lancet (London, England) 401 (10378): 747-61.